TRASLATIONAL RELEVANCE
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Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate constituted by 53 trastuzumab linked to DM1 (a tubulin polymerization inhibitor). T-DM1 is a standard 54 treatment in advanced HER2 positive metastatic breast cancer. However, resistance 55 inevitably occurs. To date, no clinical biomarker of T-DM1 resistance has been identified. 56 In this study we obtained three T-DM1 acquired resistant breast cancer in vitro models. 57 We report that cyclin B1 induction is a hallmark of T-DM1 activity in both trastuzumab 58 primary sensitive and resistant cells. In HER2 positive breast cancer cells with acquired 59 T-DM1 resistance, the drug failed to induce cyclin B1, while reducing cyclin B1 degradation 60 in these cells partially restores sensitivity. In fresh human HER2 positive breast cancer 61 explants, the induction (but not the baseline levels) of cyclin B1 by T-DM1 correlated with 62 apoptosis, suggesting that a pharmacodynamic assay to test cyclin B1 induction in breast 63 cancer patients treated with T-DM1 may help to identify early the patients more likely to 64 benefit from that drug treatment. activity, tolerability and survival than lapatinib and capecitabine (6). However, resistance 127 to T-DM1 occurs (3, 7, 8) . To date, the main T-DM1 clinical resistance mechanisms studies 128 included an exposure-response and exploratory biomarker analysis, both based on 129 patients from the EMILIA and TH3RESA trial (9-11). In the exposure-response analysis, the 130 data showed that higher T-DM1 exposure was associated with improved efficacy. This 131 analysis suggested that there is an opportunity to optimize T-DM1 dose in the patient 132 subgroup with low exposure (10). With regards to the exploratory biomarker study of the Author Manuscript Published OnlineFirst on DOI: 10.1158 /1078 EMILIA trial, focusing only in the T-DM1 group, univariate analysis of the data suggested 134 that there were no evident differences in progression free survival (PFS) related to EGFR, 135 and HER3 median mRNA concentration ratios, PIK3CA mutations status or PTEN 136 expression; patients with HER2 mRNA above the median had better outcomes on T-DM1 137 than those equal or below the median (11). In the TH3RESA phase III trial, performed in 138 heavily pre-treated HER2-positive advanced breast cancer, patients were randomized to 139 T-DM1 or treatment of physician's choice. An exploratory biomarker analysis included 140 HER2 and HER3 mRNA expression, PIK3CA mutation status and PTEN protein expression. The biomarker analyses discussed above were focused on the HER2 signaling pathway. 147 However, given the dual mechanism of action of T-DM1, we focused on resistance 148 potentially related to the cell cycle modulating effects of DM1. We identified that the of T-DM1 in a pulse-fashion (13) . The protocol is summarized in Figure 1A . with T-DM1 (7.5 g/mL) for 30 min followed by R-Phycoerythrin AffiniPure F(ab')₂
MATERIAL AND METHODS
190
Fragment Goat Fcγ Fragment Specific (Jackson ImmunoResearch; West 191 Grove, PA, USA) (1:500 dilution); for 30 min, at 4ºC. Trastuzumab (7.5 g/mL) and 192 Rituximab (MabTera, Roche; 7.5 g/mL) were used as positive and negative controls, 
RESULTS
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Generation of T-DM1 resistant HER2-positive breast cancer cells 277 We assessed the half maximal inhibitory concentration (EC50) values of T-DM1 in a panel We analyzed the effects of T-DM1 on the activity of CDK1. We first tested this effect in or the siControl were exposed to T-DM1 and cell viability was assayed after 48 hours.
406
Silencing of cyclin B1 induced a significant resistance to T-DM1 in the three parental cell 407 lines ( Figure 5A ). 408 We next tested whether increasing the levels of cyclin B1 in resistant cells might sensitize 409 them to T-DM1. Cdc20 is a regulatory subunit of the multi-subunit ubiquitin E3-ligase 410 APC/C that is responsible of cyclin B1 degradation at the end of mitosis. We silenced 411 cdc20 to promote cyclin B1 accumulation (21). As shown in Figure 5B 
